Search

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more

SWG Educational Activities

MeetingsSession on thrombocytopenias and platelet function disordersAt the EHA 2023 Congress, we held a session on ‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia.

Read more

Multiple Myeloma

The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.

Read more

Highlights from the SWG

SWG session at EHA2023The EHA2023 Congress was held in Frankfurt, Germany, in June 2023. As part of this event, the SWG held a session on Saturday, June 10, 2023. Title‘Stem cells: Clonal and mutational dynamics of hematopoietic stem cells.

Read more

EHA Congratulates EHA Research Grants 2022 Recipients

The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.

Read more

EHA-HKSH Hematology Tutorial on Lymphoid Malignancies

Dates: April 25-26, 2020 
Location: Hong Kong
Chairs: G Gaidano, J Gribben, MF Law

In 2020 EHA will co-organize the first Hematology Tutorial in Hong Kong, together with the Hong Kong Society of Haematology (HKSH).

Read more

EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement

On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.

Read more